The May 14 Science has a special section, “Tuberculosis & Malaria,” focusing on research into two “infectious diseases with high mortality and morbidity, particularly in the third world,” with articles about malaria including “Malaria's Drug Miracle in Danger,” “If Artemisinin Drugs Fail, What's Plan B?” and “The Selection Landscape of Malaria Parasites,” the last emphasizing the adaptive mechanisms of “the most virulent of the human malaria parasites, Plasmodium falciparum.” The May 22 Lancet has a report “Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Threat to Global Control of Tuberculosis.” The Science and Lancet articles cover many aspects of the diseases, but a recurring theme is development of drug resistance in the pathogens and difficulties in finding effective drug therapies to combat drug-resistant versions of the diseases.
Comprehensive medical works on drug resistance in communicable diseases are classed in 616.9041 Medical microbiology, which has the class-here note “Class here drug resistance in microorganisms” and the Relative Index entry “Drug resistance—microorganisms.” In WebDewey the LCSH “Drug resistance in microorganisms” and the MeSH “Drug Resistance, Microbial” are editorially mapped to 616.9041. The number 616.9041 is given in the schedule because notes are needed; it is actually a “number built according to instructions under 616.904,” as the note in the entry says (built with 616.904 Special topics of communicable diseases plus 1 from 01 Medical microbiology in the add table under 616.1–616.9 Specific diseases). An example of a work about drug resistance classed in 616.9041 is Antimicrobial Resistance and Implications for the Twenty-First Century.
At 616.9041 is the scatter class-elsewhere note “Class medical microbiology of a specific disease or group of diseases with the disease or group of diseases, plus notation 01 from table under 616.1–616.9, e.g., medical microbiology of tuberculosis 616.99501.” Works on drug-resistant tuberculosis that focus on the pathogen are classed in 616.99501 (built with 616.995 Tuberculosis plus 01 Medical microbiology from the add table under 616.1–616.9 Specific diseases, following the footnote instruction at 616.995). In the add table at 01 Medical microbiology is the note: “When the cause of a disease or class of diseases is known to be a single type of microorganism, use 01 without further subdivision for works about the type of microorganism.” Because tuberculosis is known to be caused by a bacterium, the 4 from the subdivision 014 Medical bacteriology is not added for tuberculosis. An example of a work classed in 616.99501 is Evolution of the Mechanisms of Drug Resistance in Mycobacterium Tuberculosis.
Works on drug-resistant malaria that focus on the pathogen are classed in 616.936201 Medical microbiology of malaria (built with 616.9362 Malaria plus 01 Medical microbiology from the add table under 616.1–616.9 Specific diseases, following the footnote instruction at 616.9362). Because malaria is known to be caused by a protozoan, the 6 from 016 Medical protozoology is not added for malaria.
General works on drug therapy are classed in 615.58 Drug therapy, which has 615.5 Therapeutics in the upward hierarchy. At 615.5 is a scatter class-elsewhere note: “Class therapies applied to a specific disease or group of diseases with the disease or group of diseases in 616–618, plus notation 06 from table under 616.1–616.9, notation 06 from table under 617, or notation 06 from table under 618.1–618.8, e.g., therapies for cardiovascular diseases 616.106.” Since class-elsewhere notes have hierarchical force, that note applies to drug therapy. Works that focus on drug therapy to fight a specific drug-resistant disease are classed with the disease plus notation 061 Drug therapy from the add table under 616.1–616.9 Specific diseases. Works on drug therapy for tuberculosis are classed in 616.995061 Drug therapy for tuberculosis, e.g., Development of New Antituberculosis Drugs. Works on drug therapy for malaria are classed in 616.9362061 Drug therapy for malaria, e.g., Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery.
Comprehensive medical works on drug resistance in communicable diseases are classed in 616.9041 Medical microbiology, which has the class-here note “Class here drug resistance in microorganisms” and the Relative Index entry “Drug resistance—microorganisms.” In WebDewey the LCSH “Drug resistance in microorganisms” and the MeSH “Drug Resistance, Microbial” are editorially mapped to 616.9041. The number 616.9041 is given in the schedule because notes are needed; it is actually a “number built according to instructions under 616.904,” as the note in the entry says (built with 616.904 Special topics of communicable diseases plus 1 from 01 Medical microbiology in the add table under 616.1–616.9 Specific diseases). An example of a work about drug resistance classed in 616.9041 is Antimicrobial Resistance and Implications for the Twenty-First Century.
At 616.9041 is the scatter class-elsewhere note “Class medical microbiology of a specific disease or group of diseases with the disease or group of diseases, plus notation 01 from table under 616.1–616.9, e.g., medical microbiology of tuberculosis 616.99501.” Works on drug-resistant tuberculosis that focus on the pathogen are classed in 616.99501 (built with 616.995 Tuberculosis plus 01 Medical microbiology from the add table under 616.1–616.9 Specific diseases, following the footnote instruction at 616.995). In the add table at 01 Medical microbiology is the note: “When the cause of a disease or class of diseases is known to be a single type of microorganism, use 01 without further subdivision for works about the type of microorganism.” Because tuberculosis is known to be caused by a bacterium, the 4 from the subdivision 014 Medical bacteriology is not added for tuberculosis. An example of a work classed in 616.99501 is Evolution of the Mechanisms of Drug Resistance in Mycobacterium Tuberculosis.
Works on drug-resistant malaria that focus on the pathogen are classed in 616.936201 Medical microbiology of malaria (built with 616.9362 Malaria plus 01 Medical microbiology from the add table under 616.1–616.9 Specific diseases, following the footnote instruction at 616.9362). Because malaria is known to be caused by a protozoan, the 6 from 016 Medical protozoology is not added for malaria.
General works on drug therapy are classed in 615.58 Drug therapy, which has 615.5 Therapeutics in the upward hierarchy. At 615.5 is a scatter class-elsewhere note: “Class therapies applied to a specific disease or group of diseases with the disease or group of diseases in 616–618, plus notation 06 from table under 616.1–616.9, notation 06 from table under 617, or notation 06 from table under 618.1–618.8, e.g., therapies for cardiovascular diseases 616.106.” Since class-elsewhere notes have hierarchical force, that note applies to drug therapy. Works that focus on drug therapy to fight a specific drug-resistant disease are classed with the disease plus notation 061 Drug therapy from the add table under 616.1–616.9 Specific diseases. Works on drug therapy for tuberculosis are classed in 616.995061 Drug therapy for tuberculosis, e.g., Development of New Antituberculosis Drugs. Works on drug therapy for malaria are classed in 616.9362061 Drug therapy for malaria, e.g., Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery.
Comments